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Metabolic Failure in Heart Failure
Although skeletal muscle is the obvious target of metabolic failure and subsequent decline in functional capacity, other tissue compartments, such as fat and bone, are similarly involved. The interaction of metabolic signals between these tissues, global effects on body composition changes, and the development of sarcopenia and cachexia will be discussed.
ANABOLIC FAILURE. Metabolic derangements in congestive heart failure (CHF) can be described globally as an overall catabolic/ anabolic imbalance (5), with blunted anabolic capacity and catabolic dominance. Anabolic blunting includes a range of signals (6) .
INSULIN RESISTANCE. Detailed information on insulin resistance can be found in the Online Appendix.
Beyond its glucoregulatory effect, insulin is 1 of the strongest anabolic stimulatory signals, acting via repression of catabolic genes and activation of transcription factor 4 (also called CREB2), and is complementary to the general amino acid control pathway (7) . The normal anabolic response to insulin and amino acid stimulation was reduced in HF patients by more than 50% because of both a blunted protein anabolic response (8) and increased proteolysis (9) . Even in nondiabetic patients, insulin resistance in HF progresses in parallel to HF severity and predicts impaired functional capacity of cardiovascular and, particularly, of muscle function (10) . Beyond morbidity, insulin resistance is a prognostic factor predicting reduced survival independent of other established prognostic markers (11) GROWTH HORMONE RESISTANCE. The growth hormone (GH)-insulin-like growth factor-1 (IGF-1) axis is a key regulatory pathway of anabolic signaling, with Akt/mTOR as downstream mediators. An acquired GH-resistant state has been described in HF, with a typical pattern of high GH levels and low IGF-1 levels (14) . GH levels were increased 3-fold in CHF patients with significant weight loss (i.e., cachexia) compared with noncachectic patients and healthy subjects. In contrast, IGF-1 levels are reduced, particularly in patients with cachexia (15) . Acquired GH resistance may explain the disappointing results of several studies that tested the GH administration as a therapeutic approach in patients with CHF (16) .
ANABOLIC STEROID METABOLISM. Anabolic deficiencies, such as low dehydroepiandrosterone sulfate, testosterone, or IGF-1 levels are common findings in HF (6) . In HF patients, this steroid metabolism impairment translates into impaired exercise capacity and symptomatic status (17) . Each anabolic hormone deficit independently predicts poor prognosis, with additive effects if more than 1 is decreased (6) .
A range of hormones involved in metabolic control, such as ghrelin (18) , leptin (13) , resistin (19) , adiponectin (20) , and natriuretic peptides (21) , are imbalanced in CHF. Additional factors, beyond the scope of These cytokines trigger multiple signaling cascades The vicious cycle of insulin resistance as an intrinsic component of heart failure (HF) pathophysiology. Several features of HF trigger insulin resistance (right section in red). In turn, insulin resistance induces a range of signals responsible for HF progression. Accordingly, insulin resistance is a major underlying mechanism of the reciprocal interaction between congestive HF and diabetes mellitus, with hyperglycemia only exerting additive effects in overt DM. AGE ¼ advanced glycation end products; PARP ¼ poly(ADP-ribose) polymerase; PKC ¼ protein kinase C; SNS ¼ sympathetic nervous system; TNF ¼ tumor necrosis factor; other abbreviations as in Figure 1 . Myostatin, a cytokine of the transforming growth factor (TGF)-beta family has garnered increasing attention as a potent muscle growth regulator. It is most abundantly expressed in skeletal muscle, with lower, but inducible, expression in the heart and in adipose tissue (27) . A systemic effect of myostatin spillover from the myocardium in HF patients may contribute to fiber type-shifting (28), insulin resistance, and skeletal muscle wasting (29) .
The skeletal muscle protein pool undergoes constant synthesis and degradation with a highly regulated and balanced turnover rate. In HF, a global imbalance accounts for muscle wasting (i.e., sarcopenia) or, ultimately, development of cachexia (see Doehner et al. (39) and is highest in cachectic patients (20, 40) . Reports on adiponectin as independent predictor of increased mortality support the significance of fat tissue and its metabolic interactions for HF pathophysiology and outcome (20, 39) . 
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HYPERURICEMIA
Hyperuricemia is commonly present in CHF and is strongly associated with disease severity (65) and mortality (66) . Accordingly, uric acid (UA) has been included as a metabolic marker and an independent factor in the Seattle Heart Failure Survival Score (67) . Nicotinic acid derivatives, such as acipimox, substantially reduce plasma free fatty acids (FFAs) via inhibition of adipose lipoproteinlipase. As assessed by positron emission tomography, acute administration of acipimox in patients with HF reduced fatty acid uptake and increased glucose uptake, but did not improve LV contractility and mechanical efficiency (77) . The PDH block may not have been alleviated acutely, and therefore, low carbohydrate oxidation would remain. Moreover, acutely reduced plasma
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FFA may deprive the heart of this important fuel.
Longer-term (28-day) therapy in patients with systolic HF was recently tested and showed no effects on LV systolic function (78) . A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure:
